Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COSTEM 2019 | MM: stem cell mobilization regimens with and without plerixafor

Nicolaus Kröger • 25 Oct 2019
COSTEM 2019
Lymphoma Multiple Myeloma Plerixafor

Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses his work on stem cell mobilization regimens with and without plerixafor in multiple myeloma (MM) patients. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Nicolaus Kröger

COSTEM 2023: congress highlights and importance 1:23
COSTEM 2023: congress highlights and importance
Nicolaus Kröger • 21 Oct 2023
The importance of bridging therapy in follicular and mantle cell lymphoma 0:35
The importance of bridging therapy in follicular and mantle cell lymphoma
Nicolaus Kröger • 28 Oct 2022
CAR-T therapy versus autoSCT in DLBCL 1:31
CAR-T therapy versus autoSCT in DLBCL
Nicolaus Kröger • 28 Oct 2022
The need for disease-modifying drugs in myelofibrosis 0:51
The need for disease-modifying drugs in myelofibrosis
Nicolaus Kröger • 28 Oct 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals